2025
Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time.
Miller J, Pelletiers W, Gross C, Mello M, Ramachandran R, Schwartz J, Suttiratana S, Varma T, Ross J. Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time. JCO Oncology Practice 2025, op2400563. PMID: 40493876, DOI: 10.1200/op-24-00563.Peer-Reviewed Original ResearchFood and Drug AdministrationOncology therapeuticsLatino patientsBlack patientsTherapeutic approvalsOlder adultsRetrospective cross-sectional studyUS Food and Drug AdministrationTrial characteristicsMinoritized patientsUS patient populationSpot trialsPivotal trialsPatient demographicsPatient populationRepresentative patientsTrial enrollmentUS Census dataDrug AdministrationPatientsStudy of trialsTrialsOncologyWomenClinical trial diversity
2023
Clinical Trial Diversity—Will We Know It When We See It?
Varma T, Gross C, Miller J. Clinical Trial Diversity—Will We Know It When We See It? JAMA Oncology 2023, 9: 765-767. PMID: 37022678, DOI: 10.1001/jamaoncol.2023.0143.Peer-Reviewed Original ResearchRanking pharmaceutical companies on clinical trial diversity
Varma T, Miller J. Ranking pharmaceutical companies on clinical trial diversity. The BMJ 2023, 380: p334. PMID: 36764687, DOI: 10.1136/bmj.p334.Peer-Reviewed Original Research
2022
Diversity in clinical research: public health and social justice imperatives
Varma T, Jones CP, Oladele C, Miller J. Diversity in clinical research: public health and social justice imperatives. Journal Of Medical Ethics 2022, 49: 200-203. PMID: 35428737, DOI: 10.1136/medethics-2021-108068.Peer-Reviewed Original Research
2021
Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatientsEquitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover
Zaidi D, Miller J, Varma T, Boatright D, Friesen P. Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover. The American Journal Of Bioethics 2021, 21: 86-88. PMID: 33616486, DOI: 10.1080/15265161.2020.1870768.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply